Pharmacogenetics of citalopram-related side effects in children with depression 
and/or anxiety disorders

Amitai, Maya; Kronenberg, Sefi; Carmel, Miri; Michaelovsky, Elena; Frisch, Amos; Brent, David; Apter, Alan; Chen, Alon; Weizman, Abraham; Fennig, Silvana

doi:10.1007/s00702-016-1585-7

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders

MPS-Authors

/persons/resource/persons129892

Chen, Alon
external;
Dept. Stress Neurobiology and Neurogenetics, Max Planck Institute of Psychiatry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Amitai, M., Kronenberg, S., Carmel, M., Michaelovsky, E., Frisch, A., Brent, D., et al. (2016). Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders. JOURNAL OF NEURAL TRANSMISSION, 123(11), 1347-1354. doi:10.1007/s00702-016-1585-7.

Cite as: https://hdl.handle.net/11858/00-001M-0000-002C-429A-F

Abstract

Pharmacogenetic approach to antidepressant (AD) response is a promising avenue toward individualizing AD treatment. This is particularly relevant in pediatric populations because of concerns about the suicide risk of serotonin selective reuptake inhibitors (SSRIs), resulting in a black-box warning. However, to date, no specific gene or polymorphism has been consistently implicated as a marker of AD side effect (SE) in the pediatric population. The aim of this study was to examine the association between polymorphisms in genes related to the serotonergic system and citalopram SE's in children and adolescents with major depressive disorder (MDD)/dysthymia and/or anxiety disorders. Outpatients (N = 87, 44 % males), aged 7-18 years with a DSM-IV-TR diagnosis of MDD/dysthymia and/or an anxiety disorder were treated in an 8-week open trial with 20-40 mg/day of citalopram. SE's were rated using a questionnaire devised specifically for this study. Association analysis between known/candidate genetic variants in three genes (5-HTR2A, 5-HTR1D beta, 5-HTR2C) and SE's was conducted. Agitation was more common in boys than girls (male:female 42.1 vs. 18.7 %, chi (2) = 5.61, df = 1, p = 0.018). Subjects with 5-HTR1D beta CC genotype showed more agitation vs. both CG and GG genotypes (CC:CG:GG 71.4 vs. 33.3 vs. 18.1 %, chi (2) = 8.99, df = 2, p = 0.011). The 5-HTR1D beta CC genotype was associated with more reports of agitation. It has been suggested that agitation may be an intermediate phenotype to suicidal behavior. Thus, it seems that 5-HTR1D beta polymorphism may be involved in citalopram-related agitation in children and adolescents treated for depression and/or anxiety.